Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide
Meditsinskiy sovet = Medical Council · 01.07.2026 · (8) · 126-137
DOI: 10.21518/ms2026-194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Meditsinskiy sovet = Medical Council, online erschienen am 01.07.2026. Verfasst von V. V. Gorban und 2 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
Introduction
The review covers the epidemiology, pathogenesis, clinic, diagnosis, and treatment of polysyndromic nonalcoholic fatty liver disease (NAFLD) associated with obesity, type 2 diabetes, and cardiovascular pathology.
Aim
To assess the key pathogenetic links of cardio-reno-hepato-metabolic syndrome in patients, as well as the therapeutic efficacy of dual-incretin drugs, such as tirzepatid and its domestic analogue sejaro. Materials and methods . The search for literature sources was carried out in the PubMed and Google Scholar databases. The selection of publications was carried out on the principle of open free access, on the analysis of abstracts and assessment of relevance.
Results
60 articles were selected for the review: 5 Russian-language and 55 foreign sources. Most publications reflect an increase in the global burden of NAFLD due to an increase in the incidence of type 2 diabetes and obesity, in the pharmacological correction of which double agonists of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), such as tirzepatid and its analogue sejaro, which are effective for weight loss, fibrosis regression and resolution of Nonalcoholic Steatohepatitis (NASH), as well as for the complex treatment of chronic metabolic diseases outside of traditional diabetes care.
Conclusions
Based on a large number of clinical trials, the review evaluated the possibilities of outpatient drug therapy for NAFLD, focused on the use of GLP-1 and GIP agonists, as well as available pharmacological drugs with a dual mechanism of action of GLP-1/GIP – tirzepatide and its domestic analogue sejaro. At the same time, sejaro shows distinct effects on pathogenic metabolic dysregulation, inflammation and fibrosis.
Zitieren
APA
Gorban, V. V., Gorban, E. V., & Kocherga, P. E. (2026). Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide. Meditsinskiy sovet = Medical Council, 126-137. https://doi.org/10.21518/ms2026-194
Vancouver
Gorban VV, Gorban EV, Kocherga PE. Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide. Meditsinskiy sovet = Medical Council. 2026:126-137. doi:10.21518/ms2026-194
BibTeX
@article{Gorban2026,
author = {Gorban, V. V. and Gorban, E. V. and Kocherga, P. E.},
title = {Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide},
journal = {Meditsinskiy sovet = Medical Council},
year = {2026},
number = {8},
pages = {126--137},
doi = {10.21518/ms2026-194}
}
EUVIMED